Quanta Pharma Tirzepatide 30mg

Quanta Tirzepatide 30mg is a pharmaceutical-grade dual agonist peptide that activates both GLP-1 and GIP receptors. This lyophilized vial from Quanta Pharma offers researchers a high-purity compound for advanced studies in glycemic control, weight management, and metabolic health. Independently lab-verified at 99.68% purity. Available for UK delivery with fast dispatch.

Tirzepatide 30mg Specifications

Tirzepatide 30mg by Quanta Pharma

Tirzepatide Research Benefits

• Dual receptor action – Targets both GLP-1 and GIP receptors for comprehensive metabolic research
• Glycemic control – Researched for enhancing insulin secretion and decreasing glucagon levels
• Appetite regulation – Shows significant effects on hunger signalling and satiety pathways
• Weight management – Investigated for substantial effects on body composition and weight loss
• Extended half-life – Approximately 5 days allows for weekly administration in research protocols

How Tirzepatide Works

Tirzepatide is a dual agonist peptide that activates two key receptors involved in metabolic regulation: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). This dual-action approach enhances insulin secretion while decreasing glucagon levels.

By targeting both GLP-1 and GIP pathways simultaneously, Tirzepatide research has demonstrated significant potential for improved glycemic control and weight management. The extended half-life of approximately 5 days makes it particularly suitable for once-weekly research protocols.

Tirzepatide vs Semaglutide

While Semaglutide targets only the GLP-1 receptor, Tirzepatide activates both GLP-1 and GIP receptors for a dual-action approach. Research suggests this may offer enhanced effects in metabolic studies, making Tirzepatide a leading compound for laboratory investigation into obesity, type 2 diabetes, and metabolic syndrome.